Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy : A postauthorization noninterventional study by A. Antinori et al.
© 2016 Antinori et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Drug Design, Development and Therapy 2016:10 1589–1603
Drug Design, Development and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1589
C l i n i C a l  T r i a l  r e p o rT
open access to scientific and medical research
open access Full Text article
http://dx.doi.org/10.2147/DDDT.S104875
effectiveness, durability, and safety of darunavir/
ritonavir in HiV-1-infected patients in routine 
clinical practice in italy: a postauthorization 
noninterventional study
andrea antinori1
paola Meraviglia2
antonella d’arminio 
Monforte3,4
antonella Castagna5,6
Cristina Mussini7
Teresa Bini4
nicola Gianotti5
Stefano rusconi8
elisa Colella8
Giuseppe airoldi9
Daniela Mancusi10
roberta Termini10
1Clinical Department, national 
institute for infectious Diseases 
“l. Spallanzani”, rome, 2Department 
of infectious Disease, “l. Sacco” 
University Hospital, 3Department of 
Health Sciences – University of Milan, 
4Clinic of infectious Diseases, “San 
paolo” Hospital, 5infectious Diseases, 
San raffaele Scientific institute, 
6Università Vita-Salute San raffaele, 
Milan, 7institute of infectious Diseases, 
University of Modena and reggio 
emilia, Modena, 8infectious Diseases 
Unit, DiBiC luigi Sacco, University 
of Milan, 9Studio associato airoldi, 
Cicogna, Ghirri, 10Janssen-Cilag Spa, 
Medical affairs, Cologno Monzese, 
Milan, italy
Abstract: Current antiretroviral (ARV) therapy for the treatment of human immunodeficiency 
virus (HIV-1)-infected patients provides long-term control of viral load (VL). Darunavir (DRV) 
is a nonpeptidomimetic protease inhibitor approved for use with a ritonavir booster (DRV/r). 
This study evaluated the effectiveness of DRV/r in combination with other ARV agents in 
routine clinical practice in Italy. In this descriptive observational study, data on utilization of 
DRV/r, under the conditions described in the marketing authorization, were collected from 
June 2009 to December 2012. Effectiveness (VL 50 copies/mL), tolerability, and durability 
in four patient groups (two DRV/r-experienced, one ARV-experienced DRV/r-naïve, and one 
ARV-naïve) were analyzed. Secondary objectives included immunological response, safety, 
and persistence/discontinuation rates. In total, 875 of 883 enrolled patients were included in the 
analysis: of these, 662 (75.7%) completed the follow-up until the end of 2012 and 213 (24.3%) 
withdrew from the study earlier. Initial DRV dose was 600 mg twice daily (67.1%) or 800 mg 
once daily (32.9%). Only 16 patients (1.8%) withdrew from the study due to virological failure. 
Virological response proportions were higher in patients virologically suppressed at study entry 
versus patients with baseline VL 50 copies/mL in each ARV-experienced group, while there 
was no consistent difference across study groups and baseline VL strata according to baseline 
CD4+ cell count. CD4+ cell count increased from study entry to last study visit in all the four 
groups. DRV/r was well tolerated, with few discontinuations due to study-emergent nonfatal 
adverse events (3.0% overall, including 2.1% drug-related) or deaths (3.0% overall, all non-
drug-related); 35.3% of patients reported 1 adverse events. These observational data show 
that DRV/r was effective and well tolerated in the whole patient population described here. 
The DRV/r-containing regimen provided viral suppression in a high percentage of patients in 
all groups, with low rates of discontinuation due to virological failure.
Keywords: darunavir/ritonavir, observational, efficacy, durable, safe
Introduction
Recent advances in highly active antiretroviral (ARV) therapy (ART) regimens for 
the treatment of human immunodeficiency virus (HIV-1)-infected patients have led to 
considerable improvements in the long-term control of viral load (VL) and prevention 
of resistance. Current guidelines recommend the use of a ritonavir-boosted protease 
inhibitor (PI/r) (alongside other options, including integrase inhibitors) as one of the 
preferred third agents in addition to a nucleoside reverse transcriptase inhibitor back-
bone including tenofovir and emtricitabine1–3 or abacavir/lamivudine.4,5
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Darunavir (DRV; TMC114) is a second-generation non-
peptidomimetic PI approved for use in combination with a 
ritonavir booster (DRV/r) (Prezista®). DRV/r is used in combi-
nation with other ARVs for the treatment of HIV-1 infection in 
adult patients and can be used in a variety of patients, ranging 
from those who are treatment-naïve to those who are highly 
experienced.6–9 The efficacy and tolerability of DRV/r have 
been evaluated in registrative prospective controlled clinical 
trials in treatment-naïve10,11 and treatment-experienced12–15 
patients with HIV-1 infection, with documented long-term 
efficacy and tolerability.13,16–18 Observational data have shown 
good long-term persistence with therapy and tolerability of 
DRV/r and support the use of this treatment in combination 
with a number of ARV agents.19–24
The primary objective of this study was to evaluate the 
effectiveness of DRV/r by collecting data on utilization of this 
agent (combined with other ARVs) in routine clinical practice 
in Italy under the conditions described in the marketing autho-
rization. The persistence of DRV/r in terms of both durability 
of virological response and number of patients remaining on 
treatment (discontinuation rate) was also evaluated because 
treatment failure is common in the real-world setting for a 
number of reasons, including lack of efficacy, loss of virologi-
cal response, resistance to treatment, adverse reactions, drug 
adherence, and patient preference.25 Furthermore, to investi-
gate whether previous clinical trial data10–18,26–28 translate into 
the setting of routine clinical practice,21–24 virological response 
with DRV/r in previously DRV-treated, ARV-experienced 
DRV-naïve, and ARV-naïve patients was assessed. Immuno-
virological responses were analyzed according to VL at study 
entry. It is well known that a virological response is usually 
more difficult to achieve in patients with a high VL or a low 
CD4+ cell count at baseline. However, a meta-analysis of clini-
cal studies conducted in ARV-experienced patients showed 
that VL reduction with DRV/r-based ART was independent 
of baseline VL and CD4+ cell count.29 This lack of association 
with baseline VL and CD4+ has also been documented in a 
clinical study of DRV/r in treatment-naïve patients11 but was 
not seen in other studies.28,30 Therefore, this study also deter-
mined the virological response according to CD4+ cell count 
at study entry to better assess the impact of this parameter on 
the virological response in DRV-naïve patients. The safety 
profile of DRV/r was also analyzed.
Materials and methods
Study design and treatment
This was an observational study in HIV-1-infected patients 
treated with DRV/r, conducted in the routine clinical setting. 
This study was registered on ClinicalTrials.gov with the identi-
fier NCT01375881. Effectiveness, tolerability, and durability 
data from four groups of patients with HIV-1 infection (two 
DRV/r-experienced and two DRV/r-naïve) were collected 
from June 2009 to December 2012. Group 1 included patients 
who had been on treatment with DRV/r since July 2007 or 
earlier, and who were part of the DRV/r Early Access Program 
(EAP) (subjects included in the EAP were heavily experienced, 
not achieving virological suppression on current regimen, at 
risk of clinical or immunological progression, and with limited 
or no treatment options); Group 2 included patients already 
receiving DRV/r in routine clinical practice, with treatment 
initiated after marketing authorization (July 2007) who had 
retrospective data from the start of DRV/r treatment available; 
Group 3 included ARV-experienced DRV-naïve patients; and 
Group 4 included ARV-naïve DRV-naïve patients.
Patients were treated with DRV/r in routine clinical 
practice according to the European Summary of Product 
Characteristics.6 In compliance with the “Circolare del 
Ministero della Salute” dated 02/09/2002 and local guidelines 
on observational studies dated 20/03/2008, the medicinal 
product was prescribed according to the current clinical 
practice and in accordance with the terms of marketing 
authorization. For the DRV-naïve patients, assignment of a 
patient to DRV/r was not decided in advance by the study 
protocol but was selected on an individual basis according to 
clinical guidelines as part of current clinical practice.
ethics
This study was approved by the local ethics committees of 
all participating centers, as follows:
– National Institute of Infectious Diseases (INMI) 
“L. Spallanzani” – Rome (Coordinating Center)
– “Umberto I” Policlinic – Rome
– “Luigi Sacco” University Hospital – Milan
– “San Raffaele” University Hospital – Milan
– “San Paolo” University Hospital – Milan
– “Tor Vergata” Policlinic – Rome
– Hospital “Spedali Civili” – Brescia
– “Cotugno” Hospital – Naples
– “Ospedali Riuniti” – Foggia
– Azienda USL n° 8 – Presidio Ospedaliero SS. 
Trinità – Cagliari
– Policlinico Universitario di Cagliari
– University Hospital “Amedeo di Savoia” – Turin
– Università Cattolica del Sacro Cuore – Policlinico 
Gemelli – Rome
– Ospedale Maggiore – Bologna
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– Hospital “San Giovanni” – Rome
– University Hospital of Modena and Reggio Emilia
– “P. Giaccone” Policlinic – Palermo
– IRCCS Policlinico S. Matteo – Pavia
– Hospital “San Gerardo” – Monza
– Ospedale di Circolo – Busto Arsizio
– Hospital “Galliera” – Genova
– University Hospital “Careggi” – Florence
– A.U.S.L. Pescara – Pescara
– Manzoni Hospital – Lecco
– University Hospital – Ferrara
– Pugliese Ciaccio Hospital – Catanzaro
– Ethics Committee for Clinical Trials of Medicines of the 
Province of Venice – Venezia
– “S. Orsola” Policlinic – Bologna
– USSL 18 Rovigo – Rovigo
– Varese Hospital – Varese
participants
Adult patients (18 years) with HIV-1 infection who initiated 
DRV/r treatment according to the label (ARV-experienced 
or ARV-naïve) or started DRV/r as part of an Italian EAP 
or who were already receiving DRV/r (provided that data 
at DRV/r start were available retrospectively) according 
to the European Summary of Product Characteristics of 
DRV were eligible for inclusion in this noninterventional 
study. All patients provided a signed and dated informed 
consent form for collection of prospective and retrospec-
tive data.
Patients with any of the following criteria were excluded 
from the study: known hypersensitivity to DRV/r or to any 
of its excipients; severe hepatic impairment (Child–Pugh 
class C); coadministration of agents known to interact with 
DRV/r; pregnancy or lactation; unable to read, understand, 
and sign the informed consent form; previously treated with 
DRV/r and discontinued for any reason; and participation in 
other interventional clinical studies.
Study end points and assessments
The primary objective was to evaluate the effectiveness of 
DRV/r used under the conditions described in the marketing 
authorization, in combination with other ARVs, in routine 
clinical practice in Italy. Effectiveness was primarily mea-
sured as virological response (defined as VL 50 copies/mL) 
in a snapshot (last observation carried forward [LOCF]) 
analysis. Secondary objectives were to evaluate the impact of 
treatment with DRV/r on immunological response, changes 
in laboratory parameters, the incidence of treatment-emergent 
adverse events (AEs), and the rates of persistence in the study 
or discontinuation for any reason or for specific reasons 
(notably virological failure).
The VL was measured in each individual center using the 
more widespread tests commercially available (eg, Abbott 
RealTime HIV-1 assay) as per manufacturer’s instructions.
The CD4+ cell count was performed in each center as 
per their clinical practice, using flow cytometry automated 
systems as per manufacturer’s instructions.
Virological outcomes were assessed based on a thresh-
old value for plasma HIV-RNA VL of 50 copies/mL 
(as per protocol, this or a lesser value being the detection 
limit in all participating centers) and are reported by group, 
by VL at study entry (50 or 50 copies/mL) within 
groups, and by baseline CD4+ (200 or 200 cells/µL) 
within baseline VL and group. Patients were followed up 
at ~1, 3, and 6 months and then every 3 months thereafter, 
in accordance with routine practice.
Blood chemistry variables (liver function tests, glucose, 
triglycerides, and total cholesterol) were determined at study 
entry and at intervals of ~6 months.
Statistical analyses
Due to the explorative character of this noninterventional 
study, no specific statistical hypothesis was formulated to 
calculate sample size when the study was planned. However, 
a sample of approximately 900 patients was considered 
adequate to describe the efficacy and safety profile of DRV/r 
in Italian patients with HIV-1 infection.
Statistical analysis was carried out using the SAS® system, 
PC release 9.2 (SAS Institute Inc., Cary, NC, USA).
The baseline of the study was the start of the prospective 
observation, and follow-up time was, therefore, calculated from 
this date to the last on-study visit, that is, the end of 2012 or 
earlier discontinuation. All subjects with HIV-1 infection who 
received 1 dose of DRV/r after enrollment were included in 
the full analysis of demographic and baseline characteristics 
as well as efficacy and safety data (full analysis population); 
however, the effective sample size for specific analyses was 
reduced in some instances because of missing data.
Data are reported for each study group and overall. 
Continuous data are described using standard descriptive 
methods, including median and other quartiles (Q
1
 and Q
3
), 
mean and standard deviation (SD), and interval estimates, 
that is, 95% confidence interval (CI) of the mean. Categori-
cal data are summarized using proportions of totals based 
on nonmissing values unless otherwise stated; exact 95% CI 
values of response proportions were calculated.
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CD4+ levels were analyzed on a LOCF basis; summary 
statistics were calculated at enrollment and at last study visit, 
including mean difference and the associated 95% CI. To 
evaluate their impact on changes from baseline to last value, 
an analysis was performed with baseline CD4+ levels and time 
to last observation as covariates within each group.
Blood chemistry variables (transaminases, glucose, 
triglycerides, and total cholesterol) were summarized at 
study entry and at intervals of 24±12 weeks using data 
from subjects with complete observations from baseline to 
72±12 weeks.
LOCF analyses of VL were performed by calculating 
the proportion of patients with virological response (viral 
suppression), that is, VL 50 copies/mL irrespective of con-
firmation at the last study visit (snapshot analysis), following 
two alternative ways to classify study discontinuations:
-	 Modified intention-to-treat (mITT) analysis: all study 
discontinuations related to medical events (virological 
failure, AEs, or death) or due to the patient (consent 
withdrawal, nonadherence or poor compliance, loss to 
follow-up) were considered as failures overriding the final 
VL value, while withdrawals for investigator’s decision 
unrelated to outcome (such as use of nonstandard DRV 
dose, enrollment in a clinical trial, completion of 12-month 
treatment of acute infection, or therapy simplification) and 
DRV/r dose modifications were not imputed as failures.
-	 On-treatment (OT) analysis: only virological failures 
were considered, study discontinuations for any other 
reason were not imputed as failures; follow-up was cen-
sored at the date of discontinuation.
The analyses of response based on VL 50 copies/mL 
were stratified by baseline VL, 50 or 50 copies/mL, 
and further (for the LOCF analysis) by baseline CD4+ 
level, 200 or 200 cells/µL. Differences in response 
proportions associated with these characteristics were tested 
within groups using Fisher’s exact test and the Cochran–
Mantel–Haenszel chi-square test.
Analyses  of  v i ro logica l  response  based on 
VL 50 copies/mL were also performed at 48 and 96 weeks. 
Patients who withdrew before the time point (48 or 96 weeks) 
for any medical or patient-related reason, as described ear-
lier, were considered as failures in the mITT analysis, while 
patients withdrawn for virological failure with the last VL 
of 50 copies/mL before the time point were considered 
as failures in the OT analysis. In either the mITT or the OT 
analysis, responders were patients still on treatment at the time 
point with a VL 50 copies/mL, while failures were defined 
as a VL 50 copies/mL at the time point, using the VL 
value closest to the time point if available within ±90 days, 
or otherwise imputing its value as 50 or 50 copies/mL 
if both the last value before this interval and the first value 
after this interval were consistently so. Patients enrolled after 
February 2011 were excluded from the analysis at 96 weeks 
as they could not have reached this time point by the end of 
the study.
To assess the impact of low (50–399 copies/mL) VL final 
values on the proportions of primary response defined earlier, 
a secondary analysis was performed with virological response 
defined as VL 400 copies/mL instead of 50 copies/mL.
AEs were summarized descriptively, in particular deaths 
and AEs that caused study interruption. Proportions and 
incidence rates were calculated. The probability of a patient 
withdrawing from the study for specific reasons was calcu-
lated over time using Kaplan–Meier curves. Separate curves 
were produced for each study group representing time since 
entry in the prospective study.
Results
patients
A total of 883 patients were enrolled in 36 Italian centers 
between June 5, 2009 and November 30, 2011. Of these, 875 
were included in the full analysis set for both effectiveness 
and safety. Follow-up continued up to the end of 2012 or 
earlier discontinuation. Flow of patients through the study 
and number of patients in the analyzed populations and 
groups are shown in Figure 1. Overall median study duration 
was 95 weeks (Q
1
–Q
3
, 74–121; mean ± SD, 93±39 weeks). 
Mean study duration was 115±39, 83±27, 91±50, and 
87±40 weeks in Groups 1, 2, 3, and 4, respectively.
Demographic and other characteristics of the study 
patients at baseline (ie, start of prospective observation) 
are shown in Table 1. The four groups differed largely in 
all important anamnestic (time since diagnosis, number 
of previous drugs), clinical (Centers for Disease Control 
and Prevention stage), and laboratory (HIV-RNA VL, 
CD4+ cell count) characteristics as they were defined as 
patient groups in different phases of their ARV therapy 
or DRV course.
The results are reported mainly descriptively by point 
and interval estimates within groups in the “Virological 
response” section; stratified analyses assessing the impact of 
baseline VL and CD4+ levels within groups have also been 
reported. Within each of Groups 1, 2, and 3, virological 
response was higher when baseline VL was 50 copies/mL 
at baseline. Overall response ratios in Groups 3 and 4 (DRV-
naïve) were lower than in Groups 1 and 2 (DRV-experienced) 
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reflecting the fact that most Group 3 patients and all Group 4 
patients had high baseline VL, while most DRV-experienced 
patients had a baseline VL 50 copies/mL. Groups 1 and 
2 were similar in the proportion of patients with baseline 
VL 50 copies/mL and in the response ratios within 
baseline VL stratum. Response ratios in Group 4 patients 
with baseline VL 50 copies/mL were higher than in 
Group 3 patients with baseline VL 50 copies/mL.
A high percentage of patients in Groups 1–3 had a long 
duration of HIV infection. The mean interval from DRV start 
to entry in the study was 41 months for patients in Group 1 
and 16 months for patients in Group 2 (Table 1). At DRV 
start, all Group 1 patients (ex-EAP) were ARV-experienced, 
while of Group 2 patients, 294 were ARV-experienced, 
50 ARV-naïve, and 63 unknown.
The median number of ARV active principles (other than 
DRV/r) reported before study start was thirteen in Group 1, 
eight in Group 2, and seven in Group 3. Overall, 61% of 
the patients received two other active ARV drugs ongoing 
at study start; tenofovir + emtricitabine were given together 
to 55.5% of the patients (91.5% of ARV-naïve), including 
11.9% with additional raltegravir (Table 2). Patients initially 
Table 1 Baseline patient characteristics and demographics (full analysis set)
Patients characteristics All (n=875) Group 1 (n=235) Group 2 (n=407) Group 3 (n=116) Group 4 (n=117)
age (years), mean ± SD 46.4±9.4 49.3±7.1 46.6±9.4 44.3±9.6 42.0±11.0
Female, n (%) 194 (22.2) 46 (19.6) 105 (25.8) 25 (21.6) 18 (15.4)
HiV-rna, n (%)
50 copies/ml 530 (62.4) 192 (85.0) 299 (75.1) 39 (35.5) 0
50–999 copies/ml 106 (12.5) 25 (11.1) 61 (15.3) 19 (17.3) 1 (0.9)
1,000–9,999 copies/ml 43 (5.1) 6 (2.7) 14 (3.5) 19 (17.3) 4 (3.5)
10,000–99,999 copies/ml 59 (6.9) 2 (0.9) 6 (1.5) 20 (18.2) 31 (27.0)
100,000–999,999 copies/ml 92 (10.8) 1 (0.4) 15 (3.8) 11 (10.0) 65 (56.5)
1,000,000 copies/ml 19 (2.2) 0 3 (0.8) 2 (1.8) 14 (12.2)
na 26 9 9 6 2
CD4+, n (%)
100 cells/µl 100 (11.7) 7 (2.7) 25 (6.2) 13 (11.7) 56 (47.9)
100–199 cells/µl 91 (10.6) 20 (8.8) 45 (11.2) 12 (10.8) 14 (12.0)
200–349 cells/µl 199 (23.2) 52 (23.0) 89 (22.1) 34 (30.6) 24 (20.5)
350–499 cells/µl 211 (24.6) 64 (28.3) 101 (25.1) 28 (25.2) 18 (15.4)
500 cells/µl 255 (29.8) 84 (37.2) 142 (35.3) 24 (21.6) 5 (4.3)
na 19 9 5 5 0
Time since HiV diagnosis, n (%)
0–1 year 146 (17.1) 0 53 (13.4) 7 (6.4) 86 (73.5)
1–10 years 146 (17.1) 6 (2.6) 81 (20.5) 34 (30.9) 25 (21.4)
10–15 years 154 (18.0) 62 (26.6) 67 (16.9) 22 (20.0) 3 (2.6)
15–20 years 192 (22.4) 89 (38.2) 85 (21.5) 17 (15.5) 1 (0.9)
20 years 218 (25.5) 76 (32.6) 110 (27.8) 30 (27.3) 2 (1.7)
na 19 2 11 6 0
CDC clinical stage, n (%)
a 258 (29.5) 29 (12.3) 138 (33.9) 36 (31.0) 55 (47.0)
B 261 (29.8) 80 (34.0) 118 (29.0) 39 (33.6) 24 (20.5)
C 356 (40.7) 126 (53.6) 151 (37.1) 41 (35.3) 38 (32.5)
Time from first DRV dose to  
study entry (days), mean ± SD
_ 1,256±224 494±382 0 0
number of other arV drugs before study start, n (%)
0 117 (13.7) 0 0 0 117
1–3 120 (14.0) 1 (0.4) 89 (22.9) 30 (25.9)
4–6 102 (11.8) 6 (2.6) 73 (18.8) 23 (19.8)
7–9 167 (19.5) 29 (12.3) 101 (26.0) 37 (31.9)
10–12 167 (19.5) 68 (28.9) 77 (19.8) 22 (19.0)
13–15 115 (13.4) 76 (32.3) 36 (9.3) 3 (2.6)
16–22 69 (8.1) 55 (23.4) 13 (3.3) 1 (0.9)
na 18 0 18 0
Notes: Group 1, patients who were part of the DrV/r early access program (eap); Group 2, patients already receiving DrV/r in routine clinical practice; Group 3, arV-
experienced DrV-naïve patients; Group 4, arV-naïve patients. 
Abbreviations: arV, antiretroviral; CDC, Centers for Disease Control and prevention; DrV/r, darunavir boosted with ritonavir; HIV, human immunodeficiency virus; 
na, not available; SD, standard deviation.
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received DRV/r 600/100 mg twice daily (bid) or 800/100 mg 
once daily (qd) according to their clinical conditions and 
current approved dose (Table 2). The majority of patients 
(96.1%) remained on their initial dosage throughout the study 
(Table 2): 557 (94.9% of 587) on 600/100 mg bid and 284 
(98.6% of 288) on 800/100 mg qd. Of the 34 patients (3.9%) 
who changed their DRV/r dose after study entry, 30 (5.1% of 
587) changed from 600/100 mg bid to 800/100 mg qd during 
the study and four (1.4% of 288) changed from 800/100 mg qd 
to 600/100 mg bid.
Virological response
Virological response proportions at the last study visit in 
the mITT analysis (ie, with medical and patient-related 
discontinuations imputed as failures) and in the OT analysis 
(ie, based on last VL only with no imputation), with virologi-
cal failure set to VL 50 copies/mL as prespecified, are shown 
in Table 3. When assessed according to baseline VL in ARV- 
experienced patients (Groups 1, 2, and 3), virological response 
was higher in patients with baseline VL 50 copies/mL 
versus those with baseline VL 50 copies/mL (P0.01 
within each group; Table 3). Within the same baseline VL 
stratum of 50 or 50 copies/mL, there was no consis-
tent difference across study groups between patients with 
baseline CD4+ 200 cells/µL and CD4+ 200 cells/µL, 
in either the OT or the mITT analyses (P0.10 within each 
group controlling for baseline VL class and within each CD4+ 
cell count; Table 3).
Table 2 Concomitant arV treatments and DrV/r dose during the study
Concomitant ARV Drugs All (n=875) Group 1 (n=235) Group 2 (n=407) Group 3 (n=116) Group 4 (n=117)
number of other arV drugs at study start, n (%)
none reported 10 (1.1) 5 (2.1) 3 (0.7) 2 (1.7) 0
1 130 (14.9) 34 (14.5) 73 (17.9) 18 (15.5) 5 (4.3)
2 534 (61.0) 115 (48.9) 239 (58.7) 78 (67.2) 102 (87.2)
3 168 (19.2) 68 (28.9) 74 (18.2) 16 (13.8) 10 (8.5)
4 33 (3.8) 13 (5.5) 18 (4.5) 2 (1.7) 0
other arV drugs at study start, n (%)
Tenofovir 542 (61.9) 124 (52.8) 238 (58.5) 73 (62.9) 107 (91.5)
emtricitabine 493 (56.3) 100 (42.6) 220 (54.1) 66 (56.9) 107 (91.5)
raltegravir 336 (38.4) 119 (50.6) 167 (40.0) 42 (36.2) 8 (6.8)
lamivudine 164 (18.7) 60 (25.5) 80 (21.0) 19 (16.4) 5 (4.3)
etravirine 86 (9.8) 35 (19.6) 45 (11.1) 6 (5.2) 0
abacavir 61 (7.0) 18 (4.9) 28 (6.9) 10 (8.6) 5 (4.3)
Maraviroc 52 (5.9) 13 (5.5) 31 (7.6) 8 (6.9) 0
Zidovudine 40 (4.6) 20 (8.5) 19 (4.7) 0 1 (0.9)
Didanosine 22 (2.5) 14 (6.0) 6 (1.5) 2 (1.7) 0
enfuvirtide 14 (1.6) 6 (2.6) 3 (0.7) 2 (1.7) 3 (2.6)
efavirenz 10 (1.1) 6 (2.6) 4 (1.0) 0 0
atazanavir 7 (0.8) 4 (1.7) 0 0 3 (2.6)
Stavudine 5 (0.6) 0 4 (1.0) 1 (0.8) 0
nevirapine 5 (0.6) 2 (0.9) 2 (0.5) 1 (0.8) 0
lopinavir 1 (0.1) 0 1 (0.2) 0 0
Frequent arV associations at study start, n (%)
Tenofovir + emtricitabine 486 (55.5) 95 (40.4) 218 (53.6) 66 (56.9) 107 (91.5)
abacavir + lamivudine 55 (6.3) 16 (6.8) 26 (6.4) 8 (6.9) 5 (4.3)
Zidovudine + lamivudine 31 (3.5) 16 (6.8) 15 (3.7) 0 0
raltegravir + lamivudine 65 (7.4) 22 (9.4) 37 (9.1) 6 (5.2) 0
raltegravir + etravirine 43 (4.9) 21 (8.9) 17 (4.2) 5 (4.3) 0
Tenofovir + emtricitabine + raltegravir 104 (11.9) 37 (15.7) 53 (13.0) 11 (9.5) 3 (2.6)
DrV dose at study start, n (%)
600 mg bid 587 (67.1) 232 (98.7) 262 (64.4) 81 (69.8) 12 (10.3)
800 mg qd 288 (32.9) 3 (1.3) 145 (35.6) 35 (30.2) 105 (89.7)
DrV dose changes after study start, n (%)
600 mg bid to 800 mg qd 30 (3.4) 15 (6.4) 8 (2.0) 2 (1.7) 5 (4.3)
800 mg qd to 600 mg bid 4 (0.5) 0 2 (0.5) 1 (0.9) 1 (0.9)
Notes: Group 1, patients who were part of the DrV/r early access program (eap); Group 2, patients already receiving DrV/r in routine clinical practice; Group 3, arV-
experienced DrV-naïve patients; Group 4, arV-naïve patients. 
Abbreviations: arV, antiretroviral; DrV/r, darunavir boosted with ritonavir 800/100 or 600/100 mg; bid, twice daily; qd, once daily.
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Virological response proportions at 48 weeks and 
96 weeks by mITT and OT, with virological failure set to 
VL 50 copies/mL, are reported in Table 4. As in the LOCF 
analysis, virological response within each ARV-experienced 
group was higher in subjects with baseline VL 50 copies/mL 
than in those with baseline VL 50 copies/mL, although not 
all differences achieved statistical significance (P0.0001 for 
all Group 1 analyses; P0.0001 for the analyses in Group 2, 
except P=0.15 by OT at 96 weeks; P=0.07 by mITT at 
48 weeks, P=0.15 by OT at 48 weeks, P=0.04 by mITT 
at 96 weeks, and P=0.46 by OT at 96 weeks in Group 3). 
Response by mITT decreased from 48 to 96 weeks in all 
groups, while OT response proportions at 96 weeks compared 
to 48 weeks decreased in the ex-EAP patients, increased in 
the ARV-naïve patients, and was approximately constant in 
the other two groups.
In secondary analyses with virological failure defined 
as VL 400 copies/mL instead of 50 copies/mL, overall 
response proportions by mITT were 181/235 (77.0%) in 
Group 1, 340/403 (84.4%) in Group 2, 72/111 (64.9%) 
in Group 3, and 86/115 (74.8%) in Group 4, and 218/229 
(95.2%), 372/395 (94.2%), 91/107 (85.0%), and 106/112 
(94.6%), respectively, by OT. Comparison with these propor-
tions shows that in the primary OT analysis, most virological 
failures in Groups 1, 2, and 4 and half in Group 3 were due 
to final VL values between 50 and 399 copies/mL.
Only 16 withdrawals due to virological failures 
occurred:
– eight in patients from the EAP study (Group 1): all except 
one harbored multiple mutations, including DRV resis-
tance associated mutations (RAMs), at study entry;
– four in other DRV-experienced patients (Group 2): three 
had only a resistance test at study entry, one of which 
had both reverse transcriptase (RT) and DRV RAMs; 
only one patient had a test both at study entry (only RT 
mutations) and at study end (no DRV RAMs);
– one in an ARV-experienced DRV-naïve patient (Group 3): 
resistance test was available only at baseline showing 
multiple PI mutations;
– three in ARV-naïve patients (Group 4): one patient had 
both study entry and follow-up resistance test with no 
mutations at both time points; one patient had only final 
resistance test with only RT mutation and no PI muta-
tions; one patient had only study start resistance test with 
no mutations.
Follow-up and treatment persistence
Crude ratios of persistence in the study at the last available 
observation were 74.9% in Group 1, 82.6% in Group 2, T
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62.9% in Group 3, and 65.8% in Group 4. Reasons for study 
discontinuation in the four groups are shown in Table 5. 
In total, 213 patients (24.3%) discontinued treatment, but 
virological failure was the reason in only 16 patients (1.8%); 
7.3% were lost to follow-up, 2.9% discontinued due to lack 
of compliance (including one patient who withdrew consent), 
3.0% dropped out due to the onset of study-related nonfatal 
AEs, and 0.6% discontinued for other patient-related reasons. 
Other study discontinuations (5.8%) occurred because of 
investigators’ decisions based on conditions present at study 
entry or for other reasons unrelated to outcome (eg, use 
of a nonstandard DRV dose, enrollment in a clinical trial, 
completion of 12-months’ treatment for acute infection, or 
therapy simplification). Overall, 26 patients (3.0%) died 
during the study; none of the deaths were considered to be 
related to DRV/r.
Kaplan–Meier curves showing, for each study group, the 
cumulative probabilities of continuing in the study or dis-
continuing for various reasons are presented in Figures 2–5. 
Persistence rates (100% minus the probability of discontinuing 
for any reason) from the start of prospective observation up to 
48 weeks (or exactly 1 year) were 90.2% (89.0%) in Group 1, 
90.2% (89.4%) in Group 2, 76.8% (76.0%) in Group 3, 
77.9% (76.2%) in Group 4, and 86.8% (85.8%) overall. Cor-
responding values from the start of prospective observation 
up to 96 weeks (or exactly 2 years) were 79.8% (79.3%), 
81.1% (80.6%), 67.4% (66.1%), 65.9% (64.7%), and 76.7% 
(76.0%). The Kaplan–Meier probability of withdrawal due 
to virological failure at 96 weeks (and identically at 2 years) 
from study start was 2.3% in Group 1, 1.1% in Group 2, 1.4% 
in Group 3, 3.5% in Group 4, and 1.8% overall, similar to 
the crude proportion of discontinuations for this reason at 
the last available observation (Figures 2–5).
immunological recovery
The mean baseline CD4+ cell counts varied between the 
four groups, being considerably higher in DRV-experienced 
patients compared with DRV-naïve patients, especially if 
ARV-naïve (Table 6). CD4+ cell counts increased from base-
line to last study visit in all four groups (Table 6): mean (95% 
CI) increases were 54 cells/µL (32, 76) in ex-EAP patients, 
59 cells/µL (44, 74) in other DRV-experienced patients, 
138 cells/µL (100, 176) in ARV-experienced DRV-naïve 
patients, and 266 cells/µL (232, 300) in ARV-naïve patients. 
The analysis of covariance showed that in all groups, the 
increase from baseline to last value was significantly greater 
for longer durations of observation (P0.0001), although the 
relationship was not necessarily linear, and in patients with 
lower baseline values (P0.05).T
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Tolerability
Safety data from 875 patients were analyzed. DRV/r-based 
treatment was well tolerated, with 35.3% of patients report-
ing 1 AE. Treatment discontinuations due to AEs were 
few (n=26, 3.0% overall): for 18 of these, a relationship 
with DRV/r treatment was not excluded by the investiga-
tor (Table 5). The most frequent AEs that led to treat-
ment discontinuation were diarrhea (n=5) and rash (n=4) 
(Table 5).
Median and other quartiles of serum biochemistry values 
for each group are reported in Table 7, only for patients with 
a complete set of observations at each time point: baseline 
(within 3 months before enrollment), 24±12, 48±12, and 
72±12 weeks. Levels of the liver enzymes alanine amin-
otransferase and aspartate aminotransferase remained stable 
from study entry through 72 weeks in DRV-experienced 
patients, decreased slightly in ARV-experienced DRV-
naïve patients, and decreased more markedly in ARV-naïve 
patients. Blood glucose concentrations remained stable in all 
groups from study entry through 72 weeks. Serum triglycer-
ide levels decreased slightly in ex-EAP patients, remained 
relatively stable in Groups 2 and 3, and increased in ARV-
naïve patients up to 48 weeks. Total cholesterol levels were 
essentially unchanged from study entry through 72 weeks in 
both DRV-experienced groups, while in ARV-experienced 
DRV-naïve patients and especially in ARV-naïve patients, 
Table 5 reasons for discontinuation from the study
Reason for discontinuation, n (%) All (n=875) Group 1 (n=235) Group 2 (n=407) Group 3 (n=116) Group 4 (n=117)
Total 213 (24.3) 59 (25.1) 71 (17.4) 43 (37.1) 40 (34.2)
Insufficient virological response 16 (1.8) 8 (3.4) 4 (1.0) 1 (0.9) 3 (2.6)
never suppressed during the study 11 5 3 1 2
rebound 5 3 1 0 1
Deatha 26 (3.0) 10 (4.3) 9 (2.2) 4 (3.4) 3 (2.6)
neoplastic disease 10 4 3 1 1
infection 4 0 3 2 0
Vascular accident 3 2 1 0 0
Hepatic failure or hepatitis 2 0 1 1 0
Bone fracture 1 1 0 0 0
Car accident 2 1 0 0 1
Suicide 1 0 0 0 1
Sudden death 1 0 1 0 0
Unknown cause 2 2 0 0 0
ae emerging during the study 26 (3.0) 3 (1.3) 9 (2.2) 6 (5.2) 8 (6.8)
neoplastic disease worseninga 3 0 2 1b 0
Gastrointestinal disordersa 2 0 1 1 0
encephalopathya 1 0 0 0 1
Myocarditis–pleurisya 1 0 0 1 0
acute renal failurea 1 0 1 0 0
rash 4 0 0 1 3
Diarrhea 5 1 2 1 1
Hyperlipidemia 3 0 2 1 0
Hyperlipidemia–diabetes 1 1 0 0 0
Hepatic enzymes increased 2 0 0 0 2
Gastrointestinal disorder unspecified 1 0 1 0 0
Coronary artery disorder 1 1 0 0 0
lipodystrophy 1 0 0 0 1
other patient-related reason 5 (0.6) 1 (0.4) 3 (0.7) 0 1 (0.9)
pregnancy 1 0 1 0 0
Concern for potential male infertility 1 0 0 0 1
Unspecified (patient’s choice) 3 1 2 0 0
lack of compliance 25 (2.9) 4 (1.7) 8 (2.0) 7 (6.0) 6 (5.1)
loss to follow-up 64 (7.3) 24 (10.2) 17 (4.2) 15 (12.9) 8 (6.8)
late decision for conditions present at entry 14 (1.6) 3 (1.3) 3 (0.7) 7 (6.0) 1 (0.9)
investigator’s decision for other reasons 37 (4.2) 6 (2.6) 18 (4.4) 3 (2.6) 10 (8.5)
Notes: aUnrelated to darunavir according to investigator. bDied 7 days after study discontinuation. Group 1, patients who were part of the DrV/r early access program 
(eap); Group 2, patients already receiving DrV/r in routine clinical practice; Group 3, arV-experienced DrV-naïve patients; Group 4, arV-naïve patients.
Abbreviations: ae, adverse event; arV, antiretroviral; DrV/r, darunavir/ritonavir.
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median values increased at 24 weeks after which they did 
not increase further.
Discussion
Although randomized, controlled clinical studies provide the 
highest level of evidence in terms of efficacy and tolerability 
for a specific treatment, observational studies are important to 
help clinical trial data be translated into the real-world setting 
because they provide information about persistence and dura-
bility in routine clinical practice that are not possible to obtain 
from clinical studies. Moreover, observational studies enroll 
an unselected population and allow long-term observation of 
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Figure 2 Kaplan–Meier curves from start of prospective observation showing study discontinuation by reason of interruption in Group 1 (n=235) – patients who were part of the 
DrV/r early access program (eap).
Abbreviations: ae, adverse event; DrV/r, darunavir/ritonavir.
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Figure 3 Kaplan–Meier curves from start of prospective observation showing study discontinuation by reason of interruption in Group 2 (n=407) – patients already receiving 
DrV/r in routine clinical practice.
Abbreviations: ae, adverse event; DrV/r, darunavir/ritonavir.
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Figure 5 Kaplan–Meier curves from start of prospective observation showing study discontinuation by reason of interruption in Group 4 (n=117) – arV-naïve patients.
Abbreviations: ae, adverse event; arV, antiretroviral.
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Figure 4 Kaplan–Meier curves from start of prospective observation showing study discontinuation by reason of interruption in Group 3 (n=116) – arV-experienced 
DrV-naïve patients.
Abbreviations: arV, antiretroviral; ae, adverse event; DrV, darunavir.
effectiveness and safety of drug combinations. This analysis of 
real-world data of DRV/r treatment is the first one to include 
the range of patients likely to be seen in clinical practice.
The results showed that most patients, regardless of 
previous clinical and treatment history, were treated with a 
stable dose of DRV/r of 600/100 mg bid or 800/100 mg qd 
and remained on study for a mean of 93±39 weeks. High 
persistence rates were seen in all groups, especially in both 
DRV-experienced groups, with an overall persistence rate 
of 75% after 24 months.
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Table 6 CD4+ cell count at study entry and at last study visit in the four groups of HiV-infected patients treated with DrV/r (loCF 
analysis)
CD4+ count, cells/μL Group 1 (n=221)a Group 2 (n=393)a Group 3 (n=102)a Group 4 (n=114)a
at study entry, median (Q1–Q3) 416 (304, 592) 403 (261, 589) 322 (203, 484) 116 (34, 302)
at study entry, mean ± SD 459±232 449±267 370±251 185±183
at last study visit, median (Q1–Q3) 488 (328, 655) 473 (321, 641) 494 (301, 612) 430 (297, 562)
at last study visit, mean ± SD 512±262 508±267 507±280 451±218
Change from study entry to last study visit, median (Q1–Q3) +42 (-39, +130) +49 (-24, +144) +105 (+24, +264) +254 (+158, +385)
Change from study entry to last study visit, mean (95% Ci) +54 (+32, +76) +59 (+44, +74) +138 (+100, +176) +266 (+232, +300)
Notes: apatients with both study entry and postbaseline CD4+ data available. Group 1, patients who were part of the DrV/r early access program (eap); Group 2, patients 
already receiving DrV/r in routine clinical practice; Group 3, arV-experienced DrV-naïve patients; Group 4, arV-naïve patients.
Abbreviations: ARV, antiretroviral; CI, confidence interval; DRV/r, darunavir/ritonavir; HIV, human immunodeficiency virus; LOCF, last observation carried forward; 
Q1, first quartile; Q3, third quartile; SD, standard deviation.
Table 7 Median (Q1–Q3) of serum biochemistry values during the study in patients with complete observations
Laboratory parameter Time (weeks) Group 1 Group 2 Group 3 Group 4
alT, U/l (n=150) (n=293) (n=67) (n=70)
0a 28 (21, 45) 27 (17, 44) 28 (20, 40) 30 (23, 52)
24±12 27 (19, 43) 28 (18, 44) 23 (15, 41) 19 (15, 28)
48±12 27 (20, 42) 26 (18, 44) 22 (16, 41) 20 (15, 29)
72±12 28 (20, 41) 28 (18, 41) 23 (16, 42) 19 (15, 26)
aST, U/l (n=148) (n=288) (n=66) (n=69)
0a 27 (20, 36) 25 (19, 39) 26 (20, 41) 29 (23, 42)
24±12 25 (19, 34) 25 (19, 36) 24 (18, 36) 21 (18, 28)
48±12 26 (19, 35) 25 (19, 35) 23 (19, 37) 21 (18, 25)
72±12 26 (19, 35) 25 (20, 34) 23 (19, 37) 21 (16, 26)
Glucose, mg/dl (n=141) (n=289) (n=67) (n=68)
0a 90 (83, 98) 89 (83, 98) 84 (78, 95) 87 (83, 96)
24±12 91 (85, 101) 88 (80, 96) 86 (80, 94) 89 (82, 100)
48±12 90 (84, 101) 88 (82, 96) 85 (79, 96) 89 (83, 98)
72±12 91 (85, 100) 88 (82, 96) 85 (78, 98) 89 (81, 96)
Triglycerides, mg/dl (n=141) (n=274) (n=60) (n=59)
0a 181 (121, 238) 154 (112, 232) 148 (94, 201) 120 (88, 148)
24±12 177 (122, 240) 164 (112, 231) 151 (109, 210) 143 (108, 217)
48±12 157 (118, 226) 152 (107, 240) 153 (97, 218) 152 (108, 244)
72±12 160 (120, 256) 148 (103, 238) 146 (96, 203) 153 (113, 199)
Total cholesterol, mg/dl (n=129) (n=268) (n=56) (n=60)
0a 209 (172, 233) 196 (158, 229) 174 (148, 204) 149 (129, 183)
24±12 213 (176, 235) 197 (167, 227) 204 (162, 226) 196 (164, 229)
48±12 197 (177, 230) 197 (164, 227) 198 (162, 226) 193 (171, 227)
72±12 211 (174, 243) 199 (167, 234) 196 (160, 232) 189 (160, 217)
Notes: aBaseline within 3 months before study start. Group 1, patients who were part of the DrV/r early access program (eap); Group 2, patients already receiving DrV/r 
in routine clinical practice; Group 3, arV-experienced DrV-naïve patients; Group 4, arV-naïve patients.
Abbreviations: alT, alanine aminotransferase; arV, antiretroviral; aST, aspartate aminotransferase; DrV/r, darunavir/ritonavir; Q1, first quartile; Q3, third quartile.
In ARV-naïve subjects, over two-thirds (68.7%) had 
a baseline VL 100,000 copies/mL and 12.2% had a 
VL 1,000,000 copies/mL. It is, therefore, very encouraging 
to report that the proportion of virological suppression in these 
previously untreated patients was 68.4% in the mITT analysis 
and 79.8% in the OT analysis. Interestingly, in ARV-naïve 
patients, 59.8% of subjects had a CD4+ cell count 200 cells/µL 
and 47.9% had a count 100 cells/µL.
The results observed in the ARV-naïve DRV-naïve patients 
were similar to those achieved in the Phase III open-label 
AntiRetroviral Therapy with TMC114 Examined In Naïve 
Subjects (ARTEMIS) trial.18 Similarly, in the 48-week once-
daily Darunavir in treatment-experienced patients (ODIN) 
trial comparing qd versus bid DRV/r in 590 ARV-experienced 
HIV-infected patients, the proportions of patients achieving 
VL 50 copies/mL were 72.1% and 70.9%, respectively 
(P0.001, qd DRV/r noninferior to bid DRV/r).14
With regard to safety, this study showed that DRV/r-
based treatment was well tolerated. Only 26 patients (3%) 
discontinued treatment due to AEs, 18 of which were deemed 
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possibly drug-related. This indicates that DRV/r is well toler-
ated in the routine clinical setting and has an overall tolerability 
profile similar to that observed in controlled clinical trials.14,18
These findings are consistent with those from controlled 
clinical studies, showing the long-term efficacy and toler-
ability of DRV/r. The current results in ARV-experienced 
DRV-naïve patients receiving DRV/r therapy are similar 
to those reported in the 48-week randomized controlled 
Phase III TITAN study of DRV/r 600/100 mg bid.15
The effectiveness, tolerability, and persistence data 
reported in this study are in agreement with those from other 
real-world studies.21–24 The body of evidence suggests that 
DRV-based therapy administered in routine care settings is 
associated with proportions of virological suppression similar 
to those seen in randomized controlled trials in most treatment-
experienced patients with HIV-infection14,18 This is true even 
in patients who have been treated for many years using several 
different ART regimens and who were failing current therapy 
due to lack of response or tolerability issues.
Limitations
The limitations of this study include the lack of a control arm 
and the different characteristics and origins of the study groups: 
two DRV-experienced groups (one from an EAP and one from 
routine clinical practice) and two DRV-naïve groups. However, 
these four groups reflect patients typically seen in daily clinical 
practice and may, therefore, help guide use of DRV/r in patients 
with HIV infection regardless of their treatment history, base-
line VL, and CD4+ cell count. Another limitation to take into 
account is that Groups 1 and 2 (DRV-experienced subjects) 
excluded patients who eventually discontinued DRV/r due to 
virological failure or drug intolerance prior to study start (this 
was an exclusion criterion because of the difficulties associated 
with collecting clinical data retrospectively).
Conclusion
These data from a routine clinical setting showed that DRV/r 
was effective and well tolerated in all HIV-infected patient 
groups, when used in either initial or switch strategies. In all 
groups, DRV/r-based ART provided effective viral suppres-
sion with long-lasting durability and a low rate of withdrawals 
due to virological failure. The overall proportion of failures, 
also including discontinuation for any reason, and the toler-
ability profile of DRV/r were favorable and similar to that 
reported in controlled clinical trials.11–15
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